New Classifications of Five Distinct “Sleep” Profi... ...
Science in the Age of AI | AI for Science Forum...
Ask the Heart Doctor | Heart Valve Disease and Sur...
High-speed imaging tracks live brain cell activity...
NAD⁺ restores memory in Alzheimer's disease models...
Mark Cuban: A Master Disrupter for American Health...
Teen girls facing the most adversity showed the biggest gain...
September 15,2026
Specialized imaging reveals hormone-driven brain changes...
September 14,2026
Submillimeter MRI reveals brain hubs that guide risky decisi...
September 12,2026
Risk of herpes zoster among breast cancer survivors in Japan...
September 11,2026
Three proteins help organs tailor shared circadian clock to ...
September 10,2026
Should you worry about melatonin and heart failure? The evid...
December 02,2025
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Today's News
GOSH BRC Showcase 2025 - Genomic medicine...
Can a twice-a-year shot help end the HIV...
Announcement of the 2025 Nobel Prize in ...
Reprogramming Stem Cells Could Cure Type...
Why MDMA did NOT get FDA approval...
More News
Remote outreach leads to six-fold increase in rural cancer screenings

Remote outreach leads to six-fold increase in rural cancer screenings

Rural women are six times more likely to get timely breast, cervical and colorectal cancer screening with remote outreach that involves interactive education and follow-up support by telephone, accord
World medicine November 23,2023
Remote outreach leads to six-fold increase in rural cancer screenings

Remote outreach leads to six-fold increase in rural cancer screenings

Rural women are six times more likely to get timely breast, cervical and colorectal cancer screening with remote outreach that involves interactive education and follow-up support by telephone, accord
World medicine November 23,2023
DLL3-Targeting Agents Are Poised to Fill Unmet Needs in SCLC

DLL3-Targeting Agents Are Poised to Fill Unmet Needs in SCLC

October 18, 2023Brittany LovelyMegan HollaschExpression of DLL3, an inhibitor ligand of the Notch pathway associated with tumorigenesis, has emerged as a target of interest for drug development.Martin
World medicine November 23,2023
DLL3-Targeting Agents Are Poised to Fill Unmet Needs in SCLC

DLL3-Targeting Agents Are Poised to Fill Unmet Needs in SCLC

October 18, 2023Brittany LovelyMegan HollaschExpression of DLL3, an inhibitor ligand of the Notch pathway associated with tumorigenesis, has emerged as a target of interest for drug development.Martin
World medicine November 23,2023
Frontline Atezolizumab Plus Chemotherapy Elicits PFS Benefit in Advanced/Recurrent Endometrial Cancer

Frontline Atezolizumab Plus Chemotherapy Elicits PFS Benefit in Advanced/Recurrent Endometrial Cancer

October 21, 2023Kristie L. KahlAtezolizumab plus standard-of-care platinum-based chemotherapy, followed by maintenance therapy with atezolizumab monotherapy, improved progression-free survival vs chem
World medicine November 23,2023
Frontline Atezolizumab Plus Chemotherapy Elicits PFS Benefit in Advanced/Recurrent Endometrial Cancer

Frontline Atezolizumab Plus Chemotherapy Elicits PFS Benefit in Advanced/Recurrent Endometrial Cancer

October 21, 2023Kristie L. KahlAtezolizumab plus standard-of-care platinum-based chemotherapy, followed by maintenance therapy with atezolizumab monotherapy, improved progression-free survival vs chem
World medicine November 23,2023
Isolating tumor-reactive blood cells to treat cancers

Isolating tumor-reactive blood cells to treat cancers

Adoptive cell therapy (ACT) has become a promising immunotherapy tool to help treat advancedmelanoma. The therapy, which harnesses immune cells collected from the patient's own tumors, could
World medicine November 23,2023
Isolating tumor-reactive blood cells to treat cancers

Isolating tumor-reactive blood cells to treat cancers

Adoptive cell therapy (ACT) has become a promising immunotherapy tool to help treat advancedmelanoma. The therapy, which harnesses immune cells collected from the patient's own tumors, could
World medicine November 23,2023
Atezolizumab Plus Chemotherapy Fails to Provide Clinical Benefit in Recurrent Ovarian Cancer

Atezolizumab Plus Chemotherapy Fails to Provide Clinical Benefit in Recurrent Ovarian Cancer

October 20, 2023Kyle DohertyPatients with recurrent ovarian cancer did not experience a statistically significant improvement in clinical outcomes such as progression-free survival and objective respo
World medicine November 23,2023
Atezolizumab Plus Chemotherapy Fails to Provide Clinical Benefit in Recurrent Ovarian Cancer

Atezolizumab Plus Chemotherapy Fails to Provide Clinical Benefit in Recurrent Ovarian Cancer

October 20, 2023Kyle DohertyPatients with recurrent ovarian cancer did not experience a statistically significant improvement in clinical outcomes such as progression-free survival and objective respo
World medicine November 23,2023
MHRA research evaluates two different approaches to cancer therapies

MHRA research evaluates two different approaches to cancer therapies

The report 'Antibody conjugates for targeted delivery of Toll-like receptor 9 agonist to the tumor tissue', published in the PLOS ONE journal, highlights MHRA research which showed that geneti
World medicine November 23,2023
MHRA research evaluates two different approaches to cancer therapies

MHRA research evaluates two different approaches to cancer therapies

The report 'Antibody conjugates for targeted delivery of Toll-like receptor 9 agonist to the tumor tissue', published in the PLOS ONE journal, highlights MHRA research which showed that geneti
World medicine November 23,2023
Frontline Zanidatamab Plus Docetaxel Yields Antitumor Activity, Safety in Advanced HER2+ Breast Cancer

Frontline Zanidatamab Plus Docetaxel Yields Antitumor Activity, Safety in Advanced HER2+ Breast Cancer

August 21, 2023Megan HollaschThe novel HER2-targeted bispecific antibody zanidatamab in combination with docetaxel demonstrated efficacy with a manageable safety profile as first-line treatment in pat
World medicine November 23,2023
Frontline Zanidatamab Plus Docetaxel Yields Antitumor Activity, Safety in Advanced HER2+ Breast Cancer

Frontline Zanidatamab Plus Docetaxel Yields Antitumor Activity, Safety in Advanced HER2+ Breast Cancer

August 21, 2023Megan HollaschThe novel HER2-targeted bispecific antibody zanidatamab in combination with docetaxel demonstrated efficacy with a manageable safety profile as first-line treatment in pat
World medicine November 23,2023
VEGF and HIF Pathway Inhibition Point Toward an Increasingly Tolerable RCC Armamentarium

VEGF and HIF Pathway Inhibition Point Toward an Increasingly Tolerable RCC Armamentarium

August 25, 2023Ashling WahnerQian (Janie) Qin, MD, discusses the current RCC treatment landscape, ongoing research with belzutifan combination therapies, and considerations for investigating CAR T-cel
World medicine November 23,2023
VEGF and HIF Pathway Inhibition Point Toward an Increasingly Tolerable RCC Armamentarium

VEGF and HIF Pathway Inhibition Point Toward an Increasingly Tolerable RCC Armamentarium

August 25, 2023Ashling WahnerQian (Janie) Qin, MD, discusses the current RCC treatment landscape, ongoing research with belzutifan combination therapies, and considerations for investigating CAR T-cel
World medicine November 23,2023
Study: People with severe mental illness less likely to attend cancer screening

Study: People with severe mental illness less likely to attend cancer screening

People with severe mental illness are less likely to attend cancer screening compared to those who do not have such conditions, according to new research from the University of Surrey and the Office f
World medicine November 23,2023
Study: People with severe mental illness less likely to attend cancer screening

Study: People with severe mental illness less likely to attend cancer screening

People with severe mental illness are less likely to attend cancer screening compared to those who do not have such conditions, according to new research from the University of Surrey and the Office f
World medicine November 23,2023
TROPiCS-02 Data Reinforce Role of Sacituzumab Govitecan as a SOC in HR+ Breast Cancer

TROPiCS-02 Data Reinforce Role of Sacituzumab Govitecan as a SOC in HR+ Breast Cancer

August 29, 2023Courtney FlahertySara M. Tolaney, MD, MPH, highlights updated survival and safety data seen with sacituzumab govitecan in patients with hormone receptor–positive, HER2-negative breast c
World medicine November 23,2023
TROPiCS-02 Data Reinforce Role of Sacituzumab Govitecan as a SOC in HR+ Breast Cancer

TROPiCS-02 Data Reinforce Role of Sacituzumab Govitecan as a SOC in HR+ Breast Cancer

August 29, 2023Courtney FlahertySara M. Tolaney, MD, MPH, highlights updated survival and safety data seen with sacituzumab govitecan in patients with hormone receptor–positive, HER2-negative breast c
World medicine November 23,2023
More News
Week’s Top
Podcasts
... Health spending has been rising across rich countries with different systems ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... At what age do people experience depression for the first time? Depression can affect people over long periods of their lives. Some people experience this condition continuously, while for others, it occu...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com